TScan Therapeutics approved a retention program featuring cash awards of $822,000 and $416,000 plus 2,400,000 and 1,050,000 restricted stock units for two executives. The structure matters to investors because cash payments and Equity vesting depend partly on continued service, a financing milestone and progress in the in vivo solid tumor program.

Key Highlights

  • CEO Gavin MacBeath and Chief Legal and Strategy Officer Zoran Zdraveski will receive the awards.
  • Cash payments include amounts due in November 2026 and February 2027.
  • RSU vesting depends on a financing milestone and continued service.

TScan Therapeutics, Inc. (NASDAQ: TCRX) approved a retention program with cash awards of $822,000 for Chief Executive Officer Gavin MacBeath and $416,000 for Chief Legal and Strategy Officer Zoran Zdraveski. The package also includes planned equity awards of 2,400,000 and 1,050,000 restricted stock units, respectively. The Compensation Committee of the Board approved the program on September 8, 2026. It is intended to retain employees needed to support TScan Therapeutics, including the two named executives.

Cash Awards Split Between Scheduled and Milestone Payments

Part of the initial cash portion is scheduled for November 2026, with the remainder due in February 2027. The milestone-related portion becomes payable when the specified clinical milestone is achieved. The terms also remain subject to applicable award agreements.

RSU Vesting Depends on Financing and Service

A portion of each RSU award is scheduled to vest when a specified financing milestone is achieved. The program therefore makes continued service a condition of equity vesting, while linking part of the cash awards to advancement of the in vivo solid tumor program. The financing milestone also determines when the initial RSU vesting occurs.